SPDL1 and Pleural effusion: Her treatment was changed to anti-PD-1 mAb + bevacizumab at 19 cycles after an increase in pleural effusion, and the increase in functional sPD-L1 occurred earlier than the clinical symptoms (Fig. 3D blue line).